หน้าแรก
Philips - คลิกที่นี่เพื่อไปที่หน้าหลัก

คำค้นหา

Core Precision guided therapy system

The Core precision guided therapy systems offer the choice of imaging and physiology on a single integrated platform.¹ Core helps provide clarity in your approach, confidence in your decisions, and convenience in your diagnostic and interventional workflows.

ติดต่อเรา

Media Gallery

Features
Clarity and confidence
One system, many choices

One system, many choices

Core supports a full suite of imaging and physiology analysis tools including FFR lesion assessment, iFR modality, iFR Scout, digital IVUS, high-resolution rotational IVUS, ChromaFlo stent apposition assessment, VH IVUS automatic tissue classification, and Pioneer Plus IVUS for peripheral procedures.*
iFR modality simplifies workflow
iFR modality simplifies workflow

iFR modality simplifies workflow

iFR modality simplifies workflow by providing a hyperemia-free measurement to assess lesion significance in as few as five heartbeats. Philips’ proprietary iFR modality has a robust body of clinical evidence with over 9,000 patients in numerous studies and peer-reviewed journal articles.⁵
iFR Scout pullback
iFR Scout pullback

iFR Scout pullback

The iFR Scout pullback shows the most significant gradient in the mid-vessel lesion with diffuse proximal disease.
Fractional Flow Reserve
Fractional Flow Reserve measurement

Fractional Flow Reserve measurement

Various clinical studies demonstrate that physiologic lesion assessment by FFR to guide routine PCI is superior to current angiography guided treatment. This measured ratio represents the potential decrease in coronary flow distal to the coronary stenosis.⁶
IVUS assesses disease
IVUS helps with disease assessment

IVUS helps with disease assessment

IVUS imaging helps physicians assess disease markers, including plaque burden percentage, lesion location and morphology, calcium volume, and the presence of thrombus. It also provides analysis of crucial parameters—like luminal cross-sectional measurements—and helps aid in disease diagnosis.
VH IVUS
Real-time lesion assessment in the cath lab

Real-time lesion assessment in the cath lab

VH IVUS Imaging provides a colorized tissue map of plaque composition with automated lumen and vessel measurements. VH IVUS technology uses advanced, proprietary spectral analysis techniques to classify plaque into 4 tissue types with 93-97% accuracy.⁹
Grayscale
Grayscale enhances procedures

Grayscale enhances procedures

Grayscale enhances angiography procedures by enabling detailed views. Angiography produces a shadowgram of contrast, while IVUS visualizes extent and location of plaque, enabling precise disease assessment, vessel, and optimal stent placement. IVUS guidance has been associated with a 74% change in PCI strategy, and reduced MACE, MI, TLR, and death in large studies.⁷,⁸
ChromaFlo
ChromaFlo stent apposition assessment

ChromaFlo stent apposition assessment

ChromaFlo highlights blood flow red for easy assessment of stent apposition, lumen size, and more. Appropriate for peripheral and coronary vessels, including left main, bifurcations, superficial femoral artery and iliac. It is designed to make lumen size and stent apposition instantly recognizable and helps identify branches, dissections, and plaque in bifurcations.
Convenience
True integration and convenience

True integration and convenience

Always on and ready for use when you need it, Core delivers convenience in your workflow with true integration. Only Philips offers the plug-and-play simplicity of digital IVUS, touchscreen control from the sterile field to get to your answers faster, and the hyperemia-free iFR modality.²,³
Optimal ease of use
Intuitive interface

Intuitive interface

Core delivers an intuitive interface for optimal ease of use as well as guided workflows and uniform controls to simplify training. Convenient measurements and labeling tools are available to document your findings. Core also offers a streamlined workflow with DICOM Worklist for patient data transfer. You can archive your results via DICOM store, DVD, or printout.²,⁴
*

Contact information

* This field is mandatory
*
*
*
*
*
*
*
*
*
By specifying your reason for contact we will be able to provide you with a better service.
We work with partners and distributors who may contact you about this Philips product on our behalf.
*
*

สิ่งนี้หมายความว่า?
Final CEE consent

ข้อกำหนดทางเทคนิค

Power requirements
Power requirements
System input
  • 100, 120V, 220, 240VAC, 50/60Hz, 1000VA Volts, volt alternating current, hertz, volt-ampere
Monitor
  • 100V – 240V 50/60Hz, 39W Volts, volt alternating current, hertz, volt-ampere
Workstation
  • 100 – 240V, 50/60Hz, 550VA, 825VA Volts, volt alternating current, hertz, volt-ampere
Dimensions
Dimensions
Workstation
  • H=17", W=10", D=16.5" Inches
Control pad (optional)
  • H=2.75", W=10.5", D=8.3" Inches
Control room controller
  • H=5", W=15", D=10" Inches
Monitor
  • H=15"– 19" (depending upon the stand extension), W=15.8", D=9.7" Inches
Connection box
  • H=9.85", W=2.95", D=7.75" Inches
Ordering Information
Ordering Information
Core system
  • CORE01
Control pad
  • CPADO1
Bedrail mount
  • MNTO1
Monitor mount
  • MNTO2

Documentation

Brochure (1)

Brochure

Related products

  • 1. 505-0100.21, Operator's Manual, Core Integrated, 3.4X (p. 18); 505-0101.16, Operator's Manual, s5 Series FFR_iFR Option, v3.4x (p.15).
  • 2. VAL RPT, S5-Core V3.4 SW with Core Control Pad, 215-0007.02.
  • 3. Product Spec. 809480-001, 202-0407.01.
  • 4. Requirements Specification Meridian VH SW, 806000-004 (pg 84).
  • 5. An iFR cut-point of 0.89 matches best with an FFR ischemic cut-point of 0.80 with a specificity of 87.8% and sensitivity of 73.0%. (iFR Operator’s Manual 505-0101.23)
  • 6. N Engl J Med. 2012;367(11):991-1001.
  • 7. Witzenbichler B et al. Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The ADAPT-DES Study. Circulation 2014 Jan: 129,4;463-470
  • 8. Ahn et al. Meta-Analysis of Outcomes After Intravascular Ultrasound Guided Versus Angiography-Guided Drug-Eluting Stent Implantation in 26,503 Patients Enrolled in Three Randomized Trials and 14 Observational Studies. Am J Cardiol 2014; 113:1338-1347

By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.

I understand